Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00350-X/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=268172138&_hsenc=p2ANqtz-8-56gVvWT1eAVDEl51ABEcO2KRBsM9Y0BmgqcDjGXbdEoX4VdqALfmvRoPFX4-ABmVItJkIe2Qy_oHAbYgiiRWLuxxSA&utm_content=268146206&utm_source=hs_email